Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07520110 · ClinicalTrials.gov registry record · Phase 3
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by University of Massachusetts, Worcester.
- Not yet
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT07520110 is a Phase 3 study that has not yet begun recruiting, run by University of Massachusetts, Worcester. The registered enrollment target is 800 participants.
The verdict
NCT07520110, a Phase 3 study, has not yet begun recruiting, sponsored by University of Massachusetts, Worcester.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in participants with IPF who are at high-risk for adverse clinical events. Approximately 800 participants with IPF will be screened. 400 participants who are at high risk for adverse clinical events (proteomic signature present) will be randomized into receiving metformin (n\~200) or matching placebo (n\~200). Participants that meet the eligibility criteria but do not have the proteomic signature (proteomic signature absent) will be contacted by phone at 12 and 24 months to review medical history.
Interventions
- DRUG Metformin
- DRUG Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07520110
The ClinicalTrials.gov registry entry for NCT07520110 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT07520110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07520110 about?
NCT07520110 is a clinical study titled "Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis". This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in p...
What is the current status of trial NCT07520110?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2026-08-01. Estimated completion is 2029-03-15.
What interventions are being tested in trial NCT07520110?
The interventions under investigation include: Metformin (DRUG), Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT07520110?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.